Cadrenal Therapeutics, Inc. Common Stock (CVKD)vsBeiGene, Ltd. (ONC)
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$5.73
-6.83%
HEALTHCARE · Cap: $15.24M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
CVKD
Avoid16
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CVKD.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CVKD
CVKD has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : CVKD
The primary concerns for CVKD are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
CVKD profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
CVKD carries more volatility with a beta of 1.07 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 16/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cadrenal Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for renal diseases and kidney-related disorders. By addressing significant unmet medical needs, Cadrenal utilizes its proprietary drug platforms to advance its promising candidates through rigorous clinical trials. With a robust commitment to scientific excellence and a patient-centric ethos, the company is poised to make a substantial impact in the renal therapeutic landscape, indicating potential for significant growth within the evolving biopharmaceutical sector.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?